JY
DMAC icon

Jeff Yass’s DiaMedica Therapeutics DMAC Stock Holding History

Jeff Yass’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,300
Closed -$69.7K – 13610
2026
Q1 		$69.7K Buy
+10,300
New +$81.6K ﹤0.01% 12511
2025
Q4 		– Sell
-19,600
Closed -$135K – 12590
2025
Q3 		$135K Buy
+19,600
New +$106K ﹤0.01% 11366
2023
Q3 		– Sell
-10,200
Closed -$44.1K – 12180
2023
Q2 		$44.1K Buy
+10,200
New +$24.8K ﹤0.01% 11385
2022
Q3 		– Sell
-59,000
Closed -$119K – 13337
2022
Q2 		$119K Buy
59,000
+12,500
+27% +$29.2K ﹤0.01% 11287
2022
Q1 		$116K Buy
46,500
+33,700
+263% +$95.6K ﹤0.01% 11790
2021
Q4 		$48K Buy
+12,800
New +$50.3K ﹤0.01% 12567

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jeff Yass's DMAC Position: Q2 2026 in Review

Jeff Yass sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 21,650 shares — an estimated $147K sold.

Jeff Yass first reported a position in DMAC in Q2 2021 and held it in 16 quarters. The position peaked at $2.11M in Q1 2025. 88 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Jeff Yass reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 21,650 DiaMedica Therapeutics shares in Q2 2026, an estimated $147K.
  • Jeff Yass first reported a position in DiaMedica Therapeutics in Q2 2021 and held it in 16 quarters.
  • Jeff Yass's DiaMedica Therapeutics position peaked at $2.11M in Q1 2025.
  • 88 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.